Challenges in glioblastoma immunotherapy: mechanisms of resistance and therapeutic approaches to overcome them

Nanotechnology and Nanocarrier-Based Drug Delivery as the Potential Therapeutic Strategy for Glioblastoma Multiforme: An Update

(2021) Jen-Fu Hsu et al.   Cancers

Eomes Impedes Durable Response to Tumor Immunotherapy by Inhibiting Stemness, Tissue Residency, and Promoting the Dysfunctional State of Intratumoral CD8+ T Cells

(2021) Runzi Sun et al.   Frontiers in Cell and Developmental Biology

Convection-enhanced drug delivery for glioblastoma: a review

(2021) Randy S. D’Amico et al.   JOURNAL OF NEURO-ONCOLOGY

Therapeutic Delivery to Central Nervous System

(2021) Katherine E. Kunigelis et al.   NEUROSURGERY CLINICS OF NORTH AMERICA

The Many Facets of Therapy Resistance and Tumor Recurrence in Glioblastoma

(2021) Anshika Goenka et al.   Cells

High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types

(2021) D.J. McGrail et al.   ANNALS OF ONCOLOGY

Making a Cold Tumor Hot: The Role of Vaccines in the Treatment of Glioblastoma

(2021) Stephen C. Frederico et al.   Frontiers in Oncology

Current FDA-Approved Therapies for High-Grade Malignant Gliomas

(2021) Jacob P. Fisher et al.   Biomedicines

The Sledgehammer in Precision Medicine: Dexamethasone and Immunotherapeutic Treatment of Glioma

(2021) Pavan S. Upadhyayula et al.   CANCER INVESTIGATION

Opening of the Blood–Brain Barrier Using Low-Intensity Pulsed Ultrasound Enhances Responses to Immunotherapy in Preclinical Glioma Models

(2021) Aria Sabbagh et al.   CLINICAL CANCER RESEARCH

A phase I/IIa study to evaluate the safety and efficacy of blood-brain barrier (BBB) opening with the SonoCloud-9 implantable ultrasound device in recurrent glioblastoma patients receiving IV carboplatin.

(2021) Ahmed Idbaih et al.   JOURNAL OF CLINICAL ONCOLOGY

The relationship between expression of PD-L1 and HIF-1α in glioma cells under hypoxia

(2021) Xing-chen Ding et al.   Journal of Hematology & Oncology

Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial

(2021) Jawad Fares et al.   LANCET ONCOLOGY

The immune landscape of common CNS malignancies: implications for immunotherapy

(2021) Martina Ott et al.   Nature Reviews Clinical Oncology

The 2021 WHO Classification of Tumors of the Central Nervous System: a summary

(2021) David N Louis et al.   NEURO-ONCOLOGY

Replication stress response defects are associated with response to immune checkpoint blockade in nonhypermutated cancers

(2021) Daniel J. McGrail et al.   Science Translational Medicine

CTLA-4 correlates with immune and clinical characteristics of glioma

(2020) Fangkun Liu et al.   Cancer Cell International

Blockade of CD73 delays glioblastoma growth by modulating the immune environment

(2020) J. H. Azambuja et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Immune checkpoint signaling and cancer immunotherapy

(2020) Xing He et al.   CELL RESEARCH

Glioblastoma-mediated immune dysfunction limits CMV-specific T cells and therapeutic responses; results from a Phase I/II trial

(2020) Shiao-Pei Weathers et al.   CLINICAL CANCER RESEARCH

A review of glioblastoma immunotherapy

(2020) Ravi Medikonda et al.   JOURNAL OF NEURO-ONCOLOGY

Adult immuno-oncology: using past failures to inform the future

(2020) Maryam Rahman et al.   NEURO-ONCOLOGY

Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma

(2020) David A. Reardon et al.   JAMA Oncology

Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma

(2020) Dipongkor Saha et al.   Journal for ImmunoTherapy of Cancer

Radiation with STAT3 blockade triggers dendritic cell-T cell interactions in the glioma microenvironment and therapeutic efficacy

(2020) Martina Ott et al.   CLINICAL CANCER RESEARCH

Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma

(2020) Kristen A Batich et al.   CLINICAL CANCER RESEARCH

Immune suppression in gliomas

(2020) Matthew M. Grabowski et al.   JOURNAL OF NEURO-ONCOLOGY

HMGB1 in Radiotherapy: A Two Headed Signal Regulating Tumor Radiosensitivity and Immunity

(2020) Yin Liao et al.   OncoTargets and Therapy

Glioma patient profiling reveals the dominant immune suppressive adenosine axis is refractory to immune function restoration

(2020) Martina Ott et al.   JCI Insight

Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8+ T Cell Anti-tumor Functions and Limits the Efficacy of Cancer Immunotherapy

(2020) Marianne Weulersse et al.   IMMUNITY

Activation of 4-1BBL+ B cells with CD40 agonism and IFNγ elicits potent immunity against glioblastoma

(2020) Catalina Lee-Chang et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Systemic Anti–PD-1 Immunotherapy Results in PD-1 Blockade on T Cells in the Cerebrospinal Fluid

(2020) Jana Portnow et al.   JAMA Oncology

New somatic TERT promoter variants enhance the Telomerase activity in Glioblastoma

(2020) Tiziana Pierini et al.   Acta Neuropathologica Communications

Brain cancer induces systemic immunosuppression through release of non-steroid soluble mediators

(2020) Katayoun Ayasoufi et al.   BRAIN

Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma

(2020) J. Bryan Iorgulescu et al.   CLINICAL CANCER RESEARCH

Unique challenges for glioblastoma immunotherapy - Discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology

(2020) Pavlina Chuntova et al.   NEURO-ONCOLOGY

Virus-specific memory T cells populate tumors and can be repurposed for tumor immunotherapy

(2019) Pamela C. Rosato et al.   Nature Communications

Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39

(2019) Maisa C. Takenaka et al.   NATURE NEUROSCIENCE

Assessment of Glioblastoma Response in the Era of Bevacizumab: Longstanding and Emergent Challenges in the Imaging Evaluation of Pseudoresponse

(2019) Octavio D. Arevalo et al.   Frontiers in Neurology

Controversial roles for dexamethasone in glioblastoma – Opportunities for novel vascular targeting therapies

(2019) Daniel Dubinski et al.   JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM

Mechanisms of immunotherapy resistance: lessons from glioblastoma

(2019) Christopher M. Jackson et al.   NATURE IMMUNOLOGY

Selective inhibition of low-affinity memory CD8+ T cells by corticosteroids

(2019) Akihiro Tokunaga et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Myeloid-derived suppressive cells promote B cell-mediated immunosuppression via transfer of PD-L1 in glioblastoma

(2019) Catalina Lee-Chang et al.   Cancer Immunology Research

Management of Glioblastoma, Present and Future

(2019) Nancy Ann Oberheim Bush et al.   World Neurosurgery

Pivotal Role of STAT3 in Shaping Glioblastoma Immune Microenvironment

(2019) Christina Piperi et al.   Cells

Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma

(2019) Sangeeta Goswami et al.   NATURE MEDICINE

Peripheral immune cells infiltrate into sites of secondary neurodegeneration after ischemic stroke

(2018) K.A. Jones et al.   BRAIN BEHAVIOR AND IMMUNITY

Tumor-derived lactate induces M2 macrophage polarization via the activation of the ERK/STAT3 signaling pathway in breast cancer

(2018) Xianmin Mu et al.   CELL CYCLE

T-cell Dysfunction in Glioblastoma: Applying a New Framework

(2018) Karolina I. Woroniecka et al.   CLINICAL CANCER RESEARCH

T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma

(2018) Karolina Woroniecka et al.   CLINICAL CANCER RESEARCH

Glioblastoma stem cell-derived exosomes induce M2 macrophages and PD-L1 expression on human monocytes

(2018) Konrad Gabrusiewicz et al.   OncoImmunology

The immune checkpoint protein PD-L1 induces and maintains regulatory T cells in glioblastoma

(2018) Joseph DiDomenico et al.   OncoImmunology

Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles

(2018) Franz L. Ricklefs et al.   Science Advances

Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations

(2018) Jun Gong et al.   Journal for ImmunoTherapy of Cancer

Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer

(2018) Kathryn C. Arbour et al.   JOURNAL OF CLINICAL ONCOLOGY

Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors

(2018) Pakawat Chongsathidkiet et al.   NATURE MEDICINE

Difference in Immunosuppressive Cells Between Peritumoral Area and Tumor Core in Glioblastoma

(2018) Ryota Tamura et al.   World Neurosurgery

Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial

(2018) Derin B. Keskin et al.   NATURE

High Levels of Eomes Promote Exhaustion of Anti-tumor CD8+ T Cells

(2018) Jing Li et al.   Frontiers in Immunology

Adenosine and adenosine receptors in the immunopathogenesis and treatment of cancer

(2017) Mohammad H. Kazemi et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas

(2017) Gary Kohanbash et al.   JOURNAL OF CLINICAL INVESTIGATION

Immunotherapy and radiation in glioblastoma

(2017) Solmaz Sahebjam et al.   JOURNAL OF NEURO-ONCOLOGY

Spatiotemporal genomic architecture informs precision oncology in glioblastoma

(2017) Jin-Ku Lee et al.   NATURE GENETICS

Is the blood–brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data

(2017) Jann N Sarkaria et al.   NEURO-ONCOLOGY

Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma

(2017) James R. Perry et al.   NEW ENGLAND JOURNAL OF MEDICINE

A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma

(2017) Donald M. O’Rourke et al.   Science Translational Medicine

Systemic T Cells Immunosuppression of Glioma Stem Cell-Derived Exosomes Is Mediated by Monocytic Myeloid-Derived Suppressor Cells

(2017) Rossana Domenis et al.   PLoS One

Functional Subclone Profiling for Prediction of Treatment-Induced Intratumor Population Shifts and Discovery of Rational Drug Combinations in Human Glioblastoma

(2016) Roman Reinartz et al.   CLINICAL CANCER RESEARCH

Survival Benefit and Safety of Bevacizumab in Combination with Erlotinib as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: A Meta-Analysis

(2016) Wei Xu et al.   CLINICAL DRUG INVESTIGATION

Advances and challenges: dendritic cell vaccination strategies for glioblastoma

(2016) Teilo H. Schaller et al.   Expert Review of Vaccines

Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial

(2016) Sarah B Goldberg et al.   LANCET ONCOLOGY

New insights into the multidimensional concept of macrophage ontogeny, activation and function

(2016) Florent Ginhoux et al.   NATURE IMMUNOLOGY

Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor

(2016) Veit Rothhammer et al.   NATURE MEDICINE

Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM

(2016) D. Mathios et al.   Science Translational Medicine

Clinical trial of blood-brain barrier disruption by pulsed ultrasound

(2016) Alexandre Carpentier et al.   Science Translational Medicine

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

(2016) Shohei Koyama et al.   Nature Communications

Macrophage Ontogeny Underlies Differences in Tumor-Specific Education in Brain Malignancies

(2016) Robert L. Bowman et al.   Cell Reports

Spatiotemporal Evolution of the Primary Glioblastoma Genome

(2015) Jinkuk Kim et al.   CANCER CELL

Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution

(2015) Hoon Kim et al.   GENOME RESEARCH

Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC).

(2015) Luis Paz-Ares et al.   JOURNAL OF CLINICAL ONCOLOGY

A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules

(2015) Aleksanteri Aspelund et al.   JOURNAL OF EXPERIMENTAL MEDICINE

New therapeutic strategies regarding endovascular treatment of glioblastoma, the role of the blood–brain barrier and new ways to bypass it

(2015) S Peschillo et al.   Journal of NeuroInterventional Surgery

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

(2015) Antoni Ribas et al.   LANCET ONCOLOGY

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

(2015) Jeffrey S Weber et al.   LANCET ONCOLOGY

Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients

(2015) Duane A. Mitchell et al.   NATURE

Structural and functional features of central nervous system lymphatic vessels

(2015) Antoine Louveau et al.   NATURE

Serum exosomes and cytokines promote a T-helper cell type 2 environment in the peripheral blood of glioblastoma patients

(2015) Larry A. Harshyne et al.   NEURO-ONCOLOGY

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

(2015) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients

(2015) Lisa B. E. Shields et al.   Radiation Oncology

The Blood–Brain Barrier

(2015) Richard Daneman et al.   Cold Spring Harbor Perspectives in Biology

Poor survival in glioblastoma patients is associated with early signs of immunosenescence in the CD4 T-cell compartment after surgery

(2015) Olesja Fornara et al.   OncoImmunology

Modulating Antiangiogenic Resistance by Inhibiting the Signal Transducer and Activator of Transcription 3 Pathway in Glioblastoma

(2015) John de Groot et al.   Oncotarget

Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing

(2015) Sofia R. Gameiro et al.   Oncotarget

Use of dexamethasone in patients with high-grade glioma: a clinical practice guideline

(2014) X. Kostaras et al.   Current Oncology

Recent Advances in Delivery Through the Blood-Brain Barrier

(2014) Jessica Larsen et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Phase 1 Clinical Trial of Intratumoral Reovirus Infusion for the Treatment of Recurrent Malignant Gliomas in Adults

(2014) Kimberly P Kicielinski et al.   MOLECULAR THERAPY

A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma

(2014) Mark R. Gilbert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma

(2014) Olivier L. Chinot et al.   NEW ENGLAND JOURNAL OF MEDICINE

Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma

(2014) A. P. Patel et al.   SCIENCE

Disruption of astrocyte–vascular coupling and the blood–brain barrier by invading glioma cells

(2014) Stacey Watkins et al.   Nature Communications

Extracellular Adenosine-Mediated Modulation of Regulatory T Cells

(2014) Akio Ohta et al.   Frontiers in Immunology

Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial

(2013) Mark R. Gilbert et al.   JOURNAL OF CLINICAL ONCOLOGY

Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial

(2013) Manfred Westphal et al.   LANCET ONCOLOGY

Tumour heterogeneity in the clinic

(2013) Philippe L. Bedard et al.   NATURE

A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application

(2013) Taku Okazaki et al.   NATURE IMMUNOLOGY

CSF-1R inhibition alters macrophage polarization and blocks glioma progression

(2013) Stephanie M Pyonteck et al.   NATURE MEDICINE

The Impact of Bevacizumab (Avastin) on Survival in Metastatic Solid Tumors - A Meta-Analysis and Systematic Review

(2013) Limor Amit et al.   PLoS One

TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal

(2013) P. J. Killela et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics

(2013) A. Sottoriva et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma

(2013) B. E. Johnson et al.   SCIENCE

Deregulated Signaling Pathways in Glioblastoma Multiforme: Molecular Mechanisms and Therapeutic Targets

(2012) Hua Mao et al.   CANCER INVESTIGATION

Unknown

(2012) Salvatore Coniglio et al.   MOLECULAR MEDICINE

Consensus on the role of human cytomegalovirus in glioblastoma

(2012) K. Dziurzynski et al.   NEURO-ONCOLOGY

Tissue concentration of systemically administered antineoplastic agents in human brain tumors

(2011) Marshall W. Pitz et al.   JOURNAL OF NEURO-ONCOLOGY

Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1

(2010) Roel G.W. Verhaak et al.   CANCER CELL

CD73: A Novel Target for Cancer Immunotherapy

(2010) B. Zhang   CANCER RESEARCH

Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma

(2010) John H. Sampson et al.   JOURNAL OF CLINICAL ONCOLOGY

Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma

(2010) J. H. Sampson et al.   NEURO-ONCOLOGY

Corticosteroid Use in Patients with Glioblastoma at First or Second Relapse Treated with Bevacizumab in the BRAIN Study

(2010) J. J. Vredenburgh et al.   ONCOLOGIST

Mediators of Glioblastoma Resistance and Invasion during Antivascular Endothelial Growth Factor Therapy

(2009) A. K. Lucio-Eterovic et al.   CLINICAL CANCER RESEARCH

Stat3 inhibition activates tumor macrophages and abrogates glioma growth in mice

(2009) Leying Zhang et al.   GLIA

CD57+ T lymphocytes and functional immune deficiency

(2009) Daniele Focosi et al.   JOURNAL OF LEUKOCYTE BIOLOGY

CNS Infiltration of Peripheral Immune Cells: D-Day for Neurodegenerative Disease?

(2009) Kavon Rezai-Zadeh et al.   Journal of Neuroimmune Pharmacology

FDA Drug Approval Summary: Bevacizumab (Avastin(R)) as Treatment of Recurrent Glioblastoma Multiforme

(2009) M. H. Cohen et al.   ONCOLOGIST

Proteomic and immunologic analyses of brain tumor exosomes

(2008) Michael W. Graner et al.   FASEB JOURNAL

Malignant Gliomas in Adults

(2008) Patrick Y. Wen et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Biology of Interleukin-2

(2007) Thomas R. Malek   Annual Review of Immunology

Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma

(2007) Duane A. Mitchell et al.   NEURO-ONCOLOGY